Head-to-head evidence
Supaglutide vs XW014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Supaglutide
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT04998032 · Phase 2/3 · completed
In this randomized, double-blind, placebo-controlled Phase 2b/3 trial in 620 adults with type 2 diabetes already taking metformin, adding once-weekly supaglutide significantly lowered blood-sugar control (HbA1c) at 24 weeks compared with adding placebo, with a clearly significant treatment difference.
XW014
Developed by Sciwind Biosciences
NCT05579314 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse events and routine safety measurements rather than a diabetes outcome such as blood sugar control, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Supaglutide's landscape · XW014's landscape